Overview
Explores various cellular targets for cancer therapy
Reviews the role of inflammatory molecules and reactive oxygen species as potential targets for drug development
Examines the potential of apoptotic and autophagy pathways as targets for anticancer therapy
Analyzes the tumor microenvironment and angiogenesis pathway as potential targets
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (11 chapters)
-
Front Matter
Keywords
About this book
This book explores potential cellular drug targets for cancer therapy. The first couple of chapters describe conventional treatment (radiotherapy, chemotherapy, and immunotherapy) & detection (biosensors) strategies for cancer. In contrast, the subsequent chapters address the role of cyclin-dependent kinases and cell cycle regulatory proteins in the growth of cancer cells and their potential as target for cancer treatment. The book then discusses the regulation of various pro-apoptotic and anti-apoptotic proteins via chemotherapeutic drugs. In addition, it examines the molecular mechanisms that are critical for mediating autophagic cell death in cancer cells. It subsequently reviews the role of reactive oxygen (ROS) species during carcinogenesis and during chemotherapy, and the potential of anti-inflammatory routes for the development of new therapeutic modulators. Lastly, it describes therapeutic strategies that target the tumor microenvironment and various angiogenic pathways for the treatment of cancer and to develop personalized medicine. Given its scope, the book is valuable resource for oncologists, cancer researchers, clinicians, and pharmaceutical industry personnel.
Editors and Affiliations
About the editor
Dr. Hardeep Singh Tuli is an Assistant Professor at the Department of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana Ambala. He previously served as a Lecturer at the Department of Applied Sciences, Institute of Science and Technology, Klawad, Yamunanagar (2009-2011), India. His research interests are focused on the isolation, characterization and biochemical evaluation of natural metabolites as anticancer agents. He has served as a reviewer for several international journals, and as a guest editor for the journal Frontiers in Pharmacology. He has more than 9 years of teaching and research experience in pharmacology, mammalian physiology, and natural products. He has published more than 70 papers in peer-reviewed international journals and authored a number of book chapters. In addition, Dr. Tuli is editorial board member of various national and international scientific research journals.
Bibliographic Information
Book Title: Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models
Editors: Hardeep Singh Tuli
DOI: https://doi.org/10.1007/978-981-15-7586-0
Publisher: Springer Singapore
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2020
Hardcover ISBN: 978-981-15-7585-3Published: 01 October 2020
Softcover ISBN: 978-981-15-7588-4Published: 02 October 2021
eBook ISBN: 978-981-15-7586-0Published: 30 September 2020
Edition Number: 1
Number of Pages: XIII, 228
Number of Illustrations: 2 b/w illustrations, 26 illustrations in colour
Topics: Cancer Research, Immunology, Cell Biology